In the present study, we investigated the inhibitory natural killer cell receptor (NKR) expression of CD94/NKG2A on PBMC after allogeneic bone marrow transplantation (BMT). The proportion of CD94 expression on PBMC was higher in patients without chronic graft-versus-host disease (cGVHD) and also in cGVHD patients with good response to conventional immunosuppressive therapy than in cGVHD patients with poor response. Also, the proportions of CD94+/CD3+ cells and CD94+/CD8+ cells were higher in cGVHD patients showing good response. In addition, the proportion of NKG2A-expressing cells was higher in patients without cGVHD than in patients with cGVHD. Therefore, chronic allostimulation after allo-BMT may augment the proportion of CD94/NKG2A-positive cells, and these cells may play some role in the regulation of alloresponse in some patients.

Moretta A, Biassoni R, Bottino C, Pende D, Vitale M, Poggi A, Mingari MC, Lorenzo M: Major histocompatibility complex class I-specific receptors on human natural killer and T lymphocytes. Immunol Rev 1997;155:105–117.
Bakker ABH, Phillips JH, Figdor CG, Lanier LL: Killer cell inhibitory receptors for MHC class I molecules regulate lysis of melanoma cells mediated by NK cells, γδ T cells, and antigen-specific CTL. J Immunol 1998;160:5239–5245.
Lanier LL: NK cell receptors. Annu Rev Immunol 1998;16:359–393.
Braud VM, Allan DSJ, O’Callaghan CA, Soderstrom K, D’Andrea A, Ogg GS, Lazetic S, Young NT, Bell JI, Phillips JH, Lanier LL, McMichael AJ: HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C. Nature 1998;391:795–799.
Mingari MC, Moretta A, Moretta L: Regulation of KIR expression in human T cells: A safe mechanism that may impair protective T-cell responses. Immunol Today 1998;19:153–157.
Leibson PJ: MHC-recognizing receptors: They’re not just for T-cells anymore. Immunity 1995;3:5–8.
Long EO, Colonna M, Lanier LL: Inhibitory MHC class I receptors on NK and T cells: A standard nomenclature. Immunol Today 1996;17:100.
Young NT, Roelen DL, Wood KJ, Welsh KI, Morris PJ, Dallman MJ: Primary alloreactive cytotoxic T lymphocytes are not commonly restricted by self-HLA class antigens. Hum Immunol 1996;50:38–46.
Yamada N, Nagatani T, Takiguchi M: T cells expressing killer cell inhibitory receptors do not carry TCR for alloantigen. Hum Immunol 1998;59:488–492.
Albi N, Ruggeri L, Aversa F, Merigiola C, Tosti A, Tognellini R, Grossi CE, Martelli MF, Velardi A: Natural killer (NK)-cell function and antileukemic activity of a large population of CD3+/CD8+ T cells expressing NK receptors for major histocompatibility complex class I after ‘three-loci’ HLA-incompatible bone marrow transplantation. Blood 1996;87:3993–4000.
Cambiaggi A, Verthuy C, Naquet P, Romagne F, Ferrier P, Biassoni R, Moretta L, Vivier E: Natural killer cell acceptance of H-2 mismatch bone marrow grafts in transgenic mice expressing HLA-Cw3 specific killer cell inhibitory receptor (CD158b). Proc Natl Acad Sci USA 1997;94:8088–8092.
Ruggeri L, Capanni M, Casucci M, Volpi I, Tosti A, Perruccio K, Urbani E, Negrin RS, Martelli MF, Velardi A: Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation. Blood 1999;94:333–339.
Cambiaggi A, Darche S, Guia S, Kourilsky P, Abastado JP, Vivier E: Modulation of T-cell functions in KIR2DL3 (CD158b) transgenic mice. Blood 1999;94:2396–2402.
Guerra N, Benlhassan K, Carayol G, Guillard M, Pardoux C, Chouaib S, Caignard A: Effect of tumor growth factor-β on NK receptor expression by allostimulated CD8+ T lymphocytes. Eur Cytokine Netw 1999;10:357–363.
Tanaka J, Mori A, Ohta S, Yamamoto Y, Kobayashi S, Hashino S, Kobayashi M, Asaka M, Imamura M: Expression of HLA-C specific natural killer cell receptor (CD158a and CD158b) on peripheral blood mononuclear cells after allogeneic bone marrow transplantation. Br J Haematol 2000;108:778–783.
Tanaka J, Mori A, Ohta S, Kobayashi S, Asaka M, Imamura M: Sequential analysis of HLA-C specific killer cell inhibitory receptor (CD158b) expressing peripheral blood mononuclear cells during chronic graft-versus-host disease. Bone Marrow Transplant 2000;26:287–290.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.